Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells

Kidney International

Volumn 63, Issue 2, 2003, Pages 464-473

  Yamagishi, Sho Ichi ^a,b   Inagaki, Yosuke ^a,b   Okamoto, Tamami ^a,b   Amano, Shinjiro ^a,b   Koga, Kohachiro ^a,b   Takeuchi, Masayoshi ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; End stage renal disease; Glycation; Prostaglandin E2; Reactive oxygen species; Tubular injury

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; CELL PROTEIN; DNA; EPITOPE; FLUORESCENT DYE; GLUCOSE; GLYCERALDEHYDE; HYDROGEN PEROXIDE; LEUCINE; MESSENGER RNA; METHYLGLYOXAL; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TRITIUM;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DIABETIC NEPHROPATHY; DNA SYNTHESIS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION;

EID: 0037246065     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00752.x     Document Type: Article

References (51)

1. FRIEDMAN EA: Diabetic renal disease, in Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice, edited by LIFKIN H, PORTE D, New York, Elsevier, 1990, pp 684-709
2. KROLEWSKI A, WARRAM J, VALSANIA P, et al: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 90:56S-61S, 1991
3. SHARMA K, ZIYADEH FN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44:1139-1146, 1995
4. TAFT J, NOLAN CJ, YEUNG SP, et al: Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 43:1046-1051, 1994
5. LANE PH, STEFFES MW, FIORETTO P, et al: Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 43:661-667, 1993
6. ZIYADEH FN, GOLDFARB S: The renal tubulointerstitium in diabetes mellitus. Kidney Int 39:464-475, 1991
7. JONES SC, SAUNDERS HJ, QI W, et al: Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia 42:1113-1119, 1999
8. GILBERT RE, COOPER ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56:1627-1637, 1999
9. FIORRETO P, MAUER M, BROCCO E, et al: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569-1576, 1996
10. DYER DG, BLACKLEDGE JA, THORPE SR, BAYNES JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654-11660, 1991
11. GRANDHEE SK, MONNIER VM: Mechanism of formation of the Mail-lard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 266:11649-11653, 1991
12. MIYATA T, VAN YPERSELE SC, KUROKAWA K, BAYNES JW: Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55:389-399, 1999
13. BROWNLEE M, CERAMI A, VLASSARA H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
14. MAKITA Z, VLASSARA H, RAYFIELD E, et al: Hemoglobin-AGE: A circulating marker of advanced glycosylation. Science 5082:651-653, 1992
15. MAKITA Z, RADOFF S, RAYFIELD EJ, et al: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
16. BUCALA R, MAKITA Z, VEGA G, et al: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445, 1994
17. YAMAGISHI S, HSU CC, TANIGUCHI M, et al: Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 213:681-687, 1995
18. YAMAGISHI S, YAMAMOTO Y, HARADA S, et al: Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett 384:103-106, 1996
19. YAMAGISHI S, YONEKURA H, YAMAMOTO Y, et al: Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 272:8723-8730, 1997
20. YAMAGISHI S, FUJIMORI H, YONEKURA H, et al: Advanced glycation endproducts inhibit prostacyclin production and induce plasmino-gen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 41:1435-1441, 1998
21. YAMAGISHI S, FUJIMORI H, YONEKURA H, et al: Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun 258:353-357, 1999
22. NISHIKAWA T, EDELSTEIN D, DU XL, et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
23. YAMAMOTO Y, KATO I, DOI T, et al: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268, 2001
24. NAKAMURA S, MAKITA Z, ISHIKAWA S, et al: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899, 1997
25. TSUCHIDA K, MAKITA Z, YAMAGISHI S, et al: Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42:579-588, 1999
26. TAKEUCHI M, BUCALA R, SUZUKI T, et al: Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 59:1094-1105, 2000
27. YAMAGISHI S, EDELSTEIN D, DU XL, et al: Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276:25096-25100, 2001
28. YAMAGISHI S, KAWAKAMI T, FUJIMORI H, et al: Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. Microvasc Res 57:329-339, 1999
29. DERYNCK R, JARRETT JA, CHEN EY, et al: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316:701-705, 1985
30. YAMAGISHI S, YONEKURA H, YAMAMOTO Y, et al: Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 79:501-509, 1999
31. YAMAGISHI S, HSU CC, KOBAYASHI K, et al: Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. Biochem Biophys Res Commun 191:840-846, 1993
32. NOMURA M, YAMAGISHI S, HARADA S, et al: Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 270:28316-28324, 1995
33. TAKEUCHI M, MAKITA Z, YANAGISAWA K, et al: Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 5:393-405, 1999
34. TAKEUCHI M, MAKITA Z, BUCALA R, et al: Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6:114-125, 2000
35. MAKITA Z, VLASSARA H, CERAMI A, et al: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
36. YAMAGISHI S, INAGAKI Y, OKAMOTO T, et al: Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells. J Biol Chem 277:20309-20315, 2002
37. OHTA K, YACHIE A, FUJIMOTO K, et al: Tubular injury as a cardinal pathologic feature in human heme oxygenase-1 deficiency. Am J Kidney Dis 35:863-870, 2000
38. KISLINGER T, FU C, HUBER B, et al: N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749, 1999
39. TSUJII M, KAWANO S, TSUJI S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716, 1999
40. CHOI YJ, CHAKRABORTY S, NGUYEN V, et al: Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor. Hum Pathol 31:1491-1497, 2000
41. ADLER S, STAHL RA, BAKER PJ, et al: Biphasic effect of oxygen radicals on prostaglandin production by rat mesangial cells. Am J Physiol 252:F743-F749, 1987
42. WENTZEL P, WELSH N, ERIKSSON UJ: Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment. Diabetes 48:813-820, 1999
43. FANG X, MOORE SA, NWANKWO JO, et al: Induction of cyclooxygen-ase-2 by overexpression of the human catalase gene in cerebral microvascular endothelial cells. J Neurochem 75:614-623, 2000
44. AOYAMA I, SHIMOKATA K, NIWA T: Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta(1) expression in spontaneously diabetic (OLETF) rats. Am J Nephrol 20:232-241, 2000
45. WANG SN, LAPAGE J, HIRSCHBERG R: Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 57:1002-1014, 2000
46. IGNOTZ RA, MASSAGUE J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337-4345, 1986
47. EDWARDS DR, MURPHY G, REYNOLDS JJ, et al: Transforming growth factor beta modulates the expression of collagenase and metallo-proteinase inhibitor. EMBO J 6:1899-1904, 1987
48. BARCELLOS-HOFF MH, DIX TA: Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10:1079-1083, 1996
49. HA H, LEE HB: Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int 58 (Suppl 77):S19-S25, 2000
50. PRICE DL, RHETT PM, THORPE SR, BAYNES JW: Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276: 48967-48972, 2001
51. ZHENG F, CAI W, MITSUHASHI T, VLASSARA H: Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse AGE-mediated cellular effects in vitro: A potential AGE sequestration therapy for diabetic nephropathy? Mol Med 7:737-747, 2001